Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | LYN | P07948 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | TYK2 | P29597 | 3/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | BMX | P51813 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 3/20 | 0.56 |
| ▸ | ITK | Q08881 | 3/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.56 |
| ▸ | TXK | P42681 | 2/20 | 0.56 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.56 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 8/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183646 | 0.87 | PDE5A (0.54) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183645 | 0.86 | PDE5A (0.60) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183711 | 0.85 | KCNA5 (0.66) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183650 | 0.85 | PDE5A (0.53) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183652 | 0.82 | PDE5A (0.51) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183649 | 0.82 | PDE5A (0.51) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183648 | 0.82 | PDE5A (0.51) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183708 | 0.81 | PDE5A (0.68) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183935 | 0.80 | PDE5A (0.67) | KCNA5JAK2LCKLYNCDK2 | |
| SCHEMBL16183714 | 0.80 | PDE5A (0.67) | KCNA5PDE5AKCNH2GBA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | KCNA5 4457/4885JAK2 1714/4885LCK 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.